Evaluating Pacira BioSciences: Insights From 8 Financial Analysts
Latest Ratings for PCRX Date Firm Action From To Feb 2022 Wedbush Maintains Outperform Feb 2022 HC Wainwright & Co. Maintains Buy Jan 2022 Barclays Maintains Overweight View More Analyst Ratings for PCRX View the Latest Analyst Ratings read more ​ ​Latest Ratings for PCRX DateFirmActionFromTo Feb 2022WedbushMaintainsOutperform Feb 2022HC Wainwright & Co.MaintainsBuy Jan 2022BarclaysMaintainsOverweight